A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 23 Jan 2013
At a glance
- Drugs AVI 7537 (Primary)
- Indications Viral infections
- Focus Pharmacokinetics
- 23 Jan 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 01 Jan 2013 Last checked against ClinicalTrials.gov record.
- 18 Sep 2012 The US FDA grants fast track status to AVI 7537 for Ebola virus infections, according to a Sarepta Therapeutics media release.